NewAmsterdam Pharma(NAMS) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Moomoo NewsMar 12 18:31 ET · Ratings
NewAmsterdam Pharma Company (NAMS) Gets a Buy From Piper Sandler
TipRanksMar 12 07:20 ET · Ratings
Director's Bold Move: Major Stock Purchase in NewAmsterdam Pharma!
TipRanksMar 6 21:15 ET
Major Stock Sale by NewAmsterdam Pharma Executive!
TipRanksMar 5 21:11 ET
NewAmsterdam Pharma(NAMS.US) Officer Sells US$3.06 Million in Common Stock
Moomoo NewsMar 5 18:12 ET
Express News | Form 144 | NewAmsterdam Pharma(NAMS.US) Officer Proposes to Sell 3.04 Million in Common Stocks
Moomoo NewsMar 4 18:55 ET

Comments

10xStockPicks

Feb 21 21:57

Esperion Therapeutics On The Verge Of Being Acquired, Upside Could Be Over 500% In The Near Future

$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...

7

6

2

10xStockPicks

Dec 16, 2024 08:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

11

2

4

10xStockPicks

Dec 16, 2024 05:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

+4

6

9

1

103848509

Dec 10, 2024 21:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly

Jaguar8

Nov 20, 2024 22:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

NAMS NewAmsterdam Pharma

Trade Overview

Capital Trend

News

Comments